| Product Name | SAIZEN SOLUTION FOR INJECTION 5.83MG/ML (6MG IN 1.03ML), 8.00MG/ML (12MG IN 1.50ML) |
| Active Ingredient | Somatropin |
| Product Registrant | MERCK PTE. LTD. |
| Date of Approval | 15/08/2023 |
| Indications: Saizen® (Only for 6 mg and 12 mg) is indicated in the treatment of:· Growth failure in prepubertal children due to chronic renal failure (CRF).· Growth disturbance due to idiopathic short stature (ISS). | |
| Product Name | COMIRNATY, CONCENTRATE FOR DISPERSION FOR INJECTION, 10 MICROGRAMS/DOSECOMIRNATY, CONCENTRATE FOR DISPERSION FOR INJECTION, 30 MICROGRAMS/DOSE |
| Active Ingredient | Tozinameran |
| Product Registrant | BionTech Pharmaceuticals Asia Pte. Ltd |
| Date of Approval | 23/08/2023 |
| Indications: COMIRNATY is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 virus, in individuals 5 years of age and older.The use of this vaccine should be in accordance with official recommendations. | |
| Product Name | IMFINZI CONCENTRATE FOR SOLUTION FOR INFUSION 50 MG/ML |
| Active Ingredient | Durvalumab |
| Product Registrant | Astrazeneca Singapore Pte Ltd |
| Date of Approval | 25/08/2023 |
| Indications: IMFINZI in combination with tremelimumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC). | |
| Product Name | BOOSTAGEN SUSPENSION FOR INJECTION |
| Active Ingredient | Diptheria Toxoid (DT), Filamentous haemagglutinin (FHA), Recombinant Pertussis Toxin (rPT), Tetanus Toxoid (TT) |
| Product Registrant | Novem Healthcare Pte Ltd |
| Date of Approval | 31/08/2023 |
| Indications: Boostagen®is indicated for:- active booster immunization against tetanus, diphtheria and pertussis in individuals from the age of 3 years onwards.- maternal immunization in pregnant women for the prevention of pertussis in infants too young to be vaccinated.Boostagen® is not indicated for primary immunization. | |
| Product Name | OLUMIANT FILM-COATED TABLET 4MGOLUMIANT FILM-COATED TABLET 2MG |
| Active Ingredient | Baricitinib |
| Product Registrant | DKSH SINGAPORE PTE. LTD. |
| Date of Approval | 31/08/2023 |
| Indications: Baricitinib is indicated for the treatment of severe alopecia areata in adult patients. | |
HSA: Health Sciences Authority
Link to the HSA announcement: https://www.hsa.gov.sg/announcements/new-drug-indication-approvals/new-drug-indication-approval—august-2023
Only Authentic Products and Genuine Medical Supplies, at POM Marketplace!
Login or Register now to access our comprehensive range of medical supplies.
Disclaimer: The information provided on this page is intended solely for healthcare professionals for informational purposes only. While we strive for accuracy, POMConnect assumes no liability for errors or omissions. The content here should not be considered a substitute for professional medical advice. POMConnect does not endorse specific treatments or external websites linked from this page. Please note that the information is accurate at the time of publication and does not account for any modifications or updates made to the original research article after its initial publish date. POM Marketplace is accessible to qualified healthcare professionals only. Any unauthorized access or use by individuals who do not meet this criteria is prohibited.
